Trends in Cardiovascular Medicine
Volume 16, Issue 6 , Pages 209-215 , August 2006

Versican Degradation and Vascular Disease

  • Richard D. Kenagy

      Affiliations

    • Department of Surgery, Seattle, WA 98109-4714, USA
    • Corresponding Author InformationAddress correspondence to: Richard D. Kenagy, PhD, Center for Cardiovascular Biology and Regenerative Medicine, University of Washington, Room 334, 815 Mercer St. Seattle, WA 98109, USA. Tel.: (+1) 206-897-1550; fax: (+1) 206-897-1553.
    • ,
  • Anna H. Plaas

      Affiliations

    • Department of Internal Medicine, University of South Florida, Tampa, FL 33612, USA
    • ,
  • Thomas N. Wight

      Affiliations

    • Hope Heart Program, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101-2795, USA

References 

  1. Arner EC. Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol. 2002;2:322–329
  2. Asakura M, Ueda Y, Nanto S, et al. Remodeling of in-stent neointima, which became thinner and transparent over 3 years—serial angiographic and angioscopic follow-up. Circulation. 1998;97:2003–2006
  3. Berceli SA, Davies MG, Kenagy RD, et al. Flow-induced neointimal regression in baboon polytetrafluoroethylene grafts is associated with decreased cell proliferation and increased apoptosis. J Vasc Surg. 2002;36:1248–1255
  4. Bingley JA, Hayward IP, Campbell GR, et al. Relationship of glycosaminoglycan and matrix changes to vascular smooth muscle cell phenotype modulation in rabbit arteries after acute injury. J Vasc Surg. 2001;33:155–164
  5. Cattaruzza S, Schiappacassi M, Ljungberg R, et al. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem. 2002;277:47626–47635
  6. Chung IM, Gold HK, Schwartz SM, et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol. 2002;40:2072–2081
  7. Cross NA, Chandrasekharan S, Jokonya N, et al. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate. 2005;63:269–275
  8. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001;20:499–508
  9. Di Cera E. Atherosclerosis: testing the water. Arterioscler Thromb Vasc Biol. 2003;23:1713–1714
  10. Evanko SP, Angello JC, Wight TN. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1004–1013
  11. Farb A, Kolodgie FD, Hwang JY, et al. Extracellular matrix changes in stented human coronary arteries. Circulation. 2004;110:940–947
  12. Finn AV, Gold HK, Tang A, et al. A novel rat model of carotid artery stenting for the understanding of restenosis in metabolic diseases. J Vasc Res. 2002;39:414–425
  13. Formato M, Farina M, Spirito R, et al. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol. 2003;24:129–135
  14. Geary RL, Nikkari ST, Wagner WD, et al. Wound healing: a paradigm for lumen narrowing after arterial reconstruction. J Vasc Surg. 1998;27:96–106
  15. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A. 1996;93:9748–9753
  16. Hirose J, Kawashima H, Yoshie O, et al. Versican interacts with chemokines and modulates cellular responses. J Biol Chem. 2001;276:5228–5234
  17. Huang R, Merrilees MJ, Braun K, et al. Inhibition of versican synthesis by antisense alters smooth muscle cell phenotype and induces elastic fiber formation in vitro and in neointima after vessel injury. Circ Res. 2006;98:370–377
  18. Imanaka-Yoshida K, Matsuura R, Isaka N, et al. Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: clinical significance of early tenascin-C expression. Virchows Arch Int J Pathol. 2001;439:185–190
  19. Inoue S, Koyama H, Miyata T, et al. Pathogenetic heterogeneity of in-stent lesion formation in human peripheral arterial disease. J Vasc Surg. 2002;35:672–678
  20. Jonsson-Rylander AC, Nilsson T, Fritsche-Danielson R, et al. Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscler Thromb Vasc Biol. 2005;25:180–185
  21. Kato M, Wang HM, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med. 1998;4:691–697
  22. Kawashima H, Atarashi K, Hirose M, et al. Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc (4,6-O-disulfate) interact with L- and P-selectin and chemokines. J Biol Chem. 2002;277:12921–12930
  23. Kenagy RD, Fischer JW, Davies MG, et al. Increased plasmin and serine proteinase activity during flow-induced intimal atrophy in baboon PTFE grafts. Arterioscler Thromb Vasc Biol. 2002;22:400–404
  24. Kenagy RD, Fischer JW, Lara S, et al. Accumulation and loss of extracellular matrix during shear stress-mediated intimal growth and regression in baboon vascular grafts. J Histochem Cytochem. 2005;53:131–140
  25. Kester M, Waybill P, Kozak M. New strategies to prevent restenosis. Am J Cardiovasc Drugs. 2001;1:77–83
  26. Kolodgie FD, Burke AP, Wight TN, et al. The accumulation of specific types of proteoglycans in eroded plaques: a role in coronary thrombosis in the absence of rupture. Curr Opin Lipidol. 2004;15:575–582
  27. Langeveld B, Roks AJM, Tio RA, et al. Rat abdominal aorta stenting: a new and reliable small animal model for in-stent restenosis. J Vasc Res. 2004;41:377–386
  28. Lemire JM, Braun KR, Maurel P, et al. Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1630–1639
  29. Lemire JM, Merrilees MJ, Braun KR, et al. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol. 2002;190:38–45
  30. Matsuura R, Isaka N, Imanaka-Yoshida K, et al. Deposition of PG-M/versican is a major cause of human coronary restenosis after percutaneous transluminal coronary angioplasty. J Pathol. 1996;180:311–316
  31. Matthews RT, Gary SC, Zerillo C, et al. Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J Biol Chem. 2000;275:22695–22703
  32. Mattsson EJR, Kohler TR, Vergel SM, et al. Increased blood flow induces regression of intimal hyperplasia. Arterioscler Thromb Vasc Biol. 1997;17:2245–2249
  33. McGee M, Wagner WD. Chondroitin sulfate anticoagulant activity is linked to water transfer: relevance to proteoglycan structure in atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:1921–1927
  34. Merrilees MJ, Lemire JM, Fischer JW, et al. Retrovirally mediated overexpression of versican V3 by arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointima after vascular injury. Circ Res. 2002;90:481–487
  35. Nicholson AC, Malik SB, Logsdon JM, et al. Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol. 2005;5:11
  36. Nikkari ST, Järveläinen HT, Wight TN, et al. Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol. 1994;144:1348–1356
  37. Nuthakki VK, Fleser PS, Malinzak LE, et al. Lysyl oxidase expression in a rat model of arterial balloon injury. J Vasc Surg. 2004;40:123–129
  38. Olin AI, Morgelin M, Sasaki T, et al. The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding. J Biol Chem. 2001;276:1253–1261
  39. Passi A, Negrini D, Albertini R, et al. The sensitivity of versican from rabbit lung to gelatinase A (MMP-2) and B (MMP-9) and its involvement in the development of hydraulic lung edema. FEBS Lett. 1999;456:93–96
  40. Perides G, Asher RA, Lark MW, et al. Glial hyaluronate-binding protein: a product of metalloproteinase digestion of versican?. Biochem J. 1995;312:377–384
  41. Sandy JD, Westling J, Kenagy RD, et al. Versican V1 proteolysis in human aorta in vivo occurs at the Glu445-Ala446 bond a site which is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem. 2001;276:13372–13378
  42. Sheng W, Wang GZ, Wang YL, et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell. 2005;16:1330–1340
  43. Somerville RP, Longpre JM, Jungers KA, et al. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J Biol Chem. 2003;278:9503–9513
  44. Theocharis AD, Tsolakis I, Hjerpe A, et al. Versican undergoes specific alterations in the fine molecular structure and organization in human aneurysmal abdominal aortas. Biomed Chromatogr. 2003;17:411–416
  45. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002;14:617–623
  46. Wight TN, Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res. 2004;94:1158–1167
  47. Wight TN, Lara S, Riessen R, et al. Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries. Am J Pathol. 1997;151:963–973
  48. Wu Y, Zhang Y, Cao L, et al. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem. 2001;276:14178–14186
  49. Wu Y, Chen L, Zheng PS, et al. beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem. 2002;277:12294–12301
  50. Yang BL, Zhang Y, Cao L, et al. Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem. 1999;72:210–220
  51. Zhang Y, Cao L, Kiani C, et al. Promotion of chondrocyte proliferation by versican mediated by G1 domain and EGF-like motifs. J Cell Biochem. 1999;73:445–457
  52. Zhang Y, Cao L, Yang BL, et al. The G3 domain of versican enhances cell proliferation via epidermal growth factor-like motifs. J Biol Chem. 1998;273:21342–21351
  53. Zheng PS, Vais D, Lapierre D, et al. PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J Cell Sci. 2004;117:5887–5895
  54. Zheng PS, Wen J, Ang LC, et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J. 2004;18:754–756
  55. Zimmermann DR, Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J. 1989;8:2975–2981

PII: S1050-1738(06)00067-3

doi: 10.1016/j.tcm.2006.03.011

Trends in Cardiovascular Medicine
Volume 16, Issue 6 , Pages 209-215 , August 2006

Article Tools

* Image Usage & Resolution